Work

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.3012

Authors: Priya Kumthekar, Alfred Rademaker, Caroline Ko, Karan Dixit, Margaret A. Schwartz, Adam M. Sonabend, Laura Sharp, Rimas Vincas Lukas, Roger Stupp, Craig Horbinski, Kathleen McCortney, Alexander H. Stegh

Institutions: Northwestern Memorial Hospital, Northwestern University, University of Chicago, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lurie Children's Hospital

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947727383

Cites:

Cited by: 52

Related to: 10